In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS and Gilead work on HIV combination drug

Executive Summary

Bristol-Myers Squibb and Gilead have formed a joint venture, Bristol-Myers Squibb & Gilead Sciences LLC, to develop and sell in the US a fixed-dosed combination of BMS' Sustiva and Gilead's Truvada, which combines two approved Gilead products Emtriva and Viread.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies